Zykadia may now be used as a first-line treatment for patients with metastatic non-small cell lung cancer whose tumors carry a specific enzyme identified through an FDA-approved test.
The drug first earned FDA approval in 2014 to treat metastatic non-small cell lung cancer patients who did not respond to the cancer drug crizotinib.
More articles on supply chain:
Pharma spent $78M on lobbying so far this year: 4 statistics
Dr. Scott Gottlieb talks drug price strategies, FDA hiring freeze: 4 takeaways
Supply chain tip of the day: Schedule daily huddles with surgical teams
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
